NCT06616597View on ClinicalTrials.gov

Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

February 13, 2025

Primary Completion Date

March 30, 2031

Study Completion Date

March 30, 2032

Conditions
Prostate Cancer (Adenocarcinoma)Metastatic Prostate Cancer
Interventions
DRUG

Abiraterone acetate

Abiraterone acetate 1000mg/ day

DRUG

Dexamethasone

Dexamethasone 0.5mg/day

DRUG

Metronidazole

Metronidazole 1500mg/ per day

Trial Locations (1)

21231

RECRUITING

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

All Listed Sponsors
collaborator

United States Department of Defense

FED

collaborator

Prostate Cancer Foundation

OTHER

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER